#MAPPs can be used to make much needed new drugs available earlier that make a difference to patients’ lives. Many can’t wait for drugs to come out in 5 or 6 years’ time. MAPPs can achieve this without compromising the evidence standards!! https://t.co/iypICzAvZT
Let’s face it, if you think of MAPPs as the intelligent combination of building blocks, then many of these building blocks are no longer controversial said Hans-Georg Eichler https://t.co/iypICzAvZT @EMA_News#adaptivepathways#Sustainability
The ADAPT SMART infographic is live on https://t.co/e3xJgeW4iu it’s a practical guide to help the various stakeholders navigate the website. Goal is to make all the information we developed available and to keep it alive for a number of years! #adaptivepathways#sustainability
#MAPPs is not a new designation, nor is it a new type of marketing authorisation. MAPPs seek to operate within the existing legal and regulatory frameworks #adaptivepathways@CASMIorg
There is still a lot to understand about practical applications of #MAPPs outside of the countries involved in @AdaptSmartIMI. We need to address the constraints in the context of the societal issues locally. https://t.co/Uj9xr1oZ91 #adaptivepathways@CASMIorg
When @beuc raised concerns about #MAPPs , we were said to be conservatives&not forward-looking. https://t.co/BgJ4lNV8tR
Interestingly enough, after 2years of project, @AdaptSmartIMI highlights the same problematic. @EMA_News@EU_Health https://t.co/i8hNq5AQ3Y
Changing process is difficult, as some payers think #MAPPs is too hard politically, too complicated, or too time consuming. However, the reality is that we have to think about new ways to handle our work @ad_schuurman@ZiNLActueel https://t.co/bFMALO6I9D #adaptivepathways
Putting stakeholders at the centre of decision-making is a key concept of the #MAPPs approach, it offers a huge potential benefit over a more traditional drug development paradigm #adaptivepathways @JacolineBouvy @NICESciAdvice https://t.co/D91THb5yJa
The @AdaptSmartIMI consortium created six framework questions that need to be addressed at key decision moments in time, the beta thalassemia case study addresses the insights and questions raised by the #MAPPs pathway #adaptivepathways
.@MIT NEWDIGS will present a case study of several of the findings of the #MAPPs project, highlighting the key decision moments that occur in the evaluation of a MAPPs product #adaptivepathways